Results 191 to 200 of about 24,853 (244)

Real-World Treatment Patterns in Patients with Atopic Dermatitis Initiating Ruxolitinib Cream: A 12-Month Follow-Up Analysis of a US Payer Claims Database. [PDF]

Clinicoecon Outcomes Res
Liu J, Desai K, Chen HP, Teng CC, Sturm D, Stockbower GE, Willey VJ.   +6 more
europepmc   +1 more source

Differential effects of GVHD therapies on intestinal epithelium. [PDF]

Blood Adv
Utrero-Rico A, Kapoor U, Berrios B, Morales G, Levine JE, Prado-Acosta M, Ferrara JLM.   +6 more
europepmc   +1 more source

Ruxolitinib reverses alopecia areata via a triple mechanism: JAK-STAT inhibition, localized oxidative stress attenuation and selective apoptosis modulation. [PDF]

J Transl Autoimmun
Zhu M, Mu H, Wang B, Han M, Ma Z, Nie X, Wang T, Zhang L, Liang F.   +8 more
europepmc   +1 more source

Cardiac Tamponade-A Rare Manifestation of Ruxolitinib Discontinuation Syndrome: A Case Report. [PDF]

Case Rep Cardiol
Hamid S, Bennet R, Yao J, Wong J.
europepmc   +1 more source

Endothelial injury is a central driver of systemic IFN-β toxicity and is reversible through Jak inhibition. [PDF]

Mol Ther Oncol
Zhang L, Pham L, Steele MB, Jenks N, Nace R, Russell SJ, Peng KW.   +6 more
europepmc   +1 more source

JAK-STAT pathway-associated skin diseases: a refined functional framework for inflammatory skin diseases. [PDF]

Front Immunol
Li B, Song X, Shan C, He J, Wang Z, Stevanovic K, Zuberbier T, Zhao Z, Zhang L.   +8 more
europepmc   +1 more source

Refractory Pembrolizumab-Induced Myocarditis-Myositis-Myasthenia Gravis Overlap Syndrome With Concurrent Hepatitis and Thyroiditis in Endometrial Carcinoma: A Case Report. [PDF]

Cureus
Beereddy D, Jonnalagadda DNMR, Murillo-Garcia DR.   +2 more
europepmc   +1 more source

Efficacy and safety of Ruxolitinib-based combination therapy in the patients with Myelofibrosis (MF): a systematic review and meta-analysis. [PDF]

Ann Med
Tan S, Li Y, Cao Y, Sun W, Hui W.
europepmc   +1 more source

Improvement of psoriasis with ruxolitinib in a patient with myeloproliferative neoplasm: a therapeutic observation. [PDF]

An Bras Dermatol
Gomide LV, Ribeiro AMQ.
europepmc   +1 more source

POIESIS: a phase III study of add-on navtemadlin in JAK inhibitor-naïve myelofibrosis patients with a suboptimal response to ruxolitinib. [PDF]

Future Oncol
Vachhani P, Yacoub A, Rampal R, Bradley T, Harrison C, Jain T, Kuykendall A, Palandri F, Mascarenhas J, Al-Ali H, Passamonti F, Rothbaum W, Verstovsek S, Heidel FH.   +13 more
europepmc   +1 more source